Discontinued — last reported Q4 '24
Cyramza® — Revenue
Eli Lilly Cyramza® — Revenue increased by 9.5% to $258.40M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 1.9%, from $253.50M to $258.40M. Over 3 years (FY 2021 to FY 2024), Cyramza® — Revenue shows relatively stable performance with a -2.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption or expanded clinical indications, while a decrease suggests heightened competition, patent expiration, or a shift in clinical treatment standards.
Detailed definition
This metric represents the total net sales generated from the specific oncology product line within the company's portfo...
Peer comparison
Comparable to specific product revenue lines in other pharmaceutical companies, often evaluated against the broader oncology portfolio performance and competitive landscape for similar therapeutic classes.
lly_segment_cyramza_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $268.70M | $253.40M | $270.30M | $230.30M | $231.30M | $232.10M | $277.70M | $236.80M | $260.30M | $224.10M | $253.50M | $229.90M | $248.90M | $236.00M | $258.40M |
| QoQ Change | — | -5.7% | +6.7% | -14.8% | +0.4% | +0.3% | +19.6% | -14.7% | +9.9% | -13.9% | +13.1% | -9.3% | +8.3% | -5.2% | +9.5% |
| YoY Change | — | — | — | — | -13.9% | -8.4% | +2.7% | +2.8% | +12.5% | -3.4% | -8.7% | -2.9% | -4.4% | +5.3% | +1.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's cyramza® — revenue?
- Eli Lilly (LLY) reported cyramza® — revenue of $258.40M in Q4 2024.
- How has Eli Lilly's cyramza® — revenue changed year-over-year?
- Eli Lilly's cyramza® — revenue increased by 1.9% year-over-year, from $253.50M to $258.40M.
- What is the long-term trend for Eli Lilly's cyramza® — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's cyramza® — revenue has grown at a -2.0% compound annual growth rate (CAGR), from $1.03B to $973.20M.
- What does cyramza® — revenue mean?
- The total revenue generated from sales of the Cyramza oncology drug.